Recent

% | $
Quotes you view appear here for quick access.

Alphabet Inc. Message Board

baxterjames120 275 posts  |  Last Activity: 14 hours ago Member since: Dec 5, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • suit filed in the U.S. could get ugly.

    The ever-present elephant in the room with John McAfee is the murder of his neighbor Gregory Faull and the charges still facing him. Years later we still don’t know exactly what happened. John claims that his neighbor Gregory Faull was murdered by the government of Belize, who had already raided his home once, in order to frame him for refusing their extortion attempts. This is a likely story and it could have happened this way. The problem is the preponderance of evidence from the other side that tells a different story.


    John McAfee’s neighbors revealed that Faull had been the primary instigator complaining about McAfee’s behavior. The community didn’t like McAfee’s aggressive “security” dogs freely roaming the beach and biting tourists, his “private army” of thugs making threats, and other activities that made him an unwelcome neighbor among the wealthy American expatriate community. One night, the four dogs in question were found poisoned to death. It seems likely that act was perpetrated by a neighbor exacting vigilante revenge for the danger they had become to the community. It is possible, and indeed likely, that it was Faull who did this. Faull and McAfee were known to be enemies and Faull had filed a formal complaint with the local government just days before his murder about McAfee dangerously firing guns into the air.

    A few days later, Gregory Faull was found dead in his home shot in the back of the head. McAfee was instantly the prime suspect but when the police went to question him he had already fled the scene. He briefly found himself an international fugitive. When he turned up in Guatemala and was arrested he feigned a heart attack and was deported back to the United States. With future extradition an unlikely prospect, Belize’s police satisfied themselves with the proceeds from auctioning off what McAfee had left behind.

    The government of Belize is indeed violent and they had used excessive force when

  • Secondary offering is a given- they have no cash and need to fund all the new initiatives and pay their new high salary tech guys they just hired.

  • no problem that I can see. Still up 15% from Tuesday

  • just scared newbies that don't understand what we have here- a gold mine!

  • watch for AH close above $4

  • Reply to

    JM is proactive- all in- full steam ahead

    by baxterjames120 Jun 30, 2016 4:06 PM
    baxterjames120 baxterjames120 Jun 30, 2016 4:07 PM Flag

    power plant to be fully operational by August 1 2016- just 30 days from now!!!

  • The co has secured a location with contracted low cost hydro power in central Washington state to launch a facility generating over two PetaHash in processing power.
    This facility is expected to be fully operational by Aug 1, 2016, and has expansion capacity to nearly 10 PetaHash.
    Recently, the Company has been testing a smaller scale operation with 'positive' results. The testing has allowed MGT to optimize its production software as well as provide experience to its team in building out and managing a profitable mining center, according to the co.
    "In order to meet the processing demand for our future cyber security products that are Blockchain based, MGT will need a large number of ASIC computers. Our announced strategy is particularly cost effective, as mining computers are perfectly suited for this task and can earn a great ROI until we utilize the processing power of these super-fast machines to support the future revenue streams of our products. Further, we pleased that Robert has agreed to join us and use his expertise to grow the project."

  • Slow and steady wins the race.

  • baxterjames120 by baxterjames120 Jun 20, 2016 9:32 PM Flag

    mmune Pharmaceuticals is on a mission to improve patients’ lives through targeted medicine. The company is well-funded by a diverse investment base. Clinical work focuses on severe and/or rare inflammatory diseases and cancer.

    What Many Investors May Not Know About IMNP:

    Our lead asset, Bertilimumab, is a first in class antibody, with on going phase 2 trials in multiple indications and potential sales of $ 5B per year
    Our Immuno-Oncology pipeline, includes 3 mid-to-late stage assets and two platforms with a focus on check point inhibitors.
    NanoCyclo is a potentially game changing topical treatment for atopic dermatitis and psoriasis with potential sales of $1B and 505(b)2 accelerated track.
    IMNP NYC based new management team is poised for execution with multiple 2016-17 milestones.

    mmune Pharmaceuticals is on a mission to improve patients’ lives through targeted medicine. The company is well-funded by a diverse investment base. Clinical work focuses on severe and/or rare inflammatory diseases and cancer.

    What Many Investors May Not Know About IMNP:

    Our lead asset, Bertilimumab, is a first in class antibody, with on going phase 2 trials in multiple indications and potential sales of $ 5B per year
    Our Immuno-Oncology pipeline, includes 3 mid-to-late stage assets and two platforms with a focus on check point inhibitors.
    NanoCyclo is a potentially game changing topical treatment for atopic dermatitis and psoriasis with potential sales of $1B and 505(b)2 accelerated track.
    IMNP NYC based new management team is poised for execution with multiple 2016-17 milestones.

  • .52+ for close.

  • Why is he still "proposed" Are their legal reasons? I don't get it.

  • baxterjames120 baxterjames120 Jun 10, 2016 9:24 PM Flag

    I'm loading up more Monday. I believe we have seen the bottom. This is a long term buy and hold for those patient enough to see the incredible potential

  • Butamax and Gevo Enter Into Global Patent Cross-License and Settlement Agreements to Accelerate Development of Markets for Bio-Based Isobutanol and End All Litigation

    ENGLEWOOD, Colo., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO) and Butamax Advanced Biofuels, LLC, a joint venture between BP and DuPont, announced that they have entered into worldwide patent cross-license and settlement agreements, ending a patent dispute related to technologies for the production of bio-based isobutanol. This settlement ends all of the lawsuits and creates a new relationship between the companies, aimed at leveraging each other's strengths and accelerating development of competitive supply for bio-based isobutanol.

    The cross-license agreement grants both parties patent licenses to all fields for isobutanol and is structured to develop robust and sustainable isobutanol markets. The license will be royalty bearing for Butamax in certain fields and royalty bearing for Gevo in other fields. There are also a number of fields that are royalty-free for both companies. Both parties can sell up to 30 million gallons per year royalty-free into any field.

    The accompanying Factsheet provides further details of the cross-license and settlement agreements.

    Butamax will take the lead role in developing the market for isobutanol as an on-road gasoline blendstock. This will include progressing ongoing programs to gain required EPA approvals for mainstream use of 16% isobutanol as a gasoline blend component. Butamax has also conducted joint research with Underwriters Laboratories (UL), which has demonstrated that these blends can be used safely in fuel storage and dispensing equipment meeting current UL standards. It is expected that UL's guidance will clear the way for state government agencies to consider and approve the dispensing of biobutanol-gasoline fuel blends in the U.S.

    In parallel, Gevo will lead development of the jet fuel market. Gevo has been producing and selling alcohol-to-jet fuel (ATJ) derived from isobutanol since 2011. To date, Gevo's ATJ has been produced at its demo biorefinery in Silsbee, TX, using isobutanol produced at its Luverne, MN, fermentation facility. The company has successfully flown tests flights with the U.S. Air Force, U.S. Army, and U.S. Navy and now expects to secure the MIL-SPEC certification (JP-8 and JP-5) enabling bids on future RFPs for renewable jet fuel by the Defense Logistics Agency. Gevo also intends to begin test flights with the commercial aviation industry, including Alaska Airlines, following receipt of ASTM International certification, expected before the end of 2015.

    While Butamax and Gevo have cross-licensed all of their patents for making and using isobutanol, both parties will have their own biocatalyst and process technologies. Both Butamax and Gevo are free to license their respective technology packages to third parties. A third party licensee would be granted a sub-license, and would be subject to terms and conditions that are consistent with the cross-license between Butamax and Gevo.

    "We are very pleased to have reached this amicable and fair settlement. Setting up the marketing relationships, as we have done, brings to bear the capabilities of each of the companies," said Dr. Patrick Gruber, Gevo's Chief Executive Officer. "We very much look forward to developing a very large, growing and profitable isobutanol market in conjunction with Butamax."

    "The aim of these agreements is to accelerate development of markets for bio-based isobutanol," commented Butamax Chief Executive Officer Paul Beckwith. "This will create exciting opportunities for ethanol producers to expand their businesses by becoming isobutanol producers, at the same time enabling the most competitive isobutanol supply for customers."

    Both parties have agreed to keep all details relating to these agreements confidential, other than what is disclosed in this press release and the attachment, or is otherwise required to be disclosed by law.

    About Butamax

    Butamax™ Advanced Biofuels, LLC was formed to develop and commercialize biobutanol as a next generation renewable biofuel and chemical. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to end use. For more information, visit www.butamax.com.

    Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

    About Gevo

    Gevo is a leading renewable technology, chemical products, and next generation biofuels company. Gevo has developed proprietary technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstocks. Gevo's strategy is to commercialize biobased alternatives to petroleum-based products to allow for the optimization of fermentation facilities' assets, with the ultimate goal of maximizing cash flows from the operation of those assets. Gevo produces isobutanol, ethanol and high-value animal feed at its fermentation plant in Luverne, Minn. Gevo has also developed technology to produce hydrocarbon products from renewable alcohols. Gevo currently operates a biorefinery in Silsbee, Texas, in collaboration with South Hampton Resources Inc., to produce renewable jet fuel, octane, and ingredients for plastics like polyester. Gevo has a marquee list of partners including The Coca-Cola Company, Toray Industries Inc. and Total SA, among others. Gevo is committed to a sustainable bio-based economy that meets society's needs for plentiful food and clean air and water.

  • you gotta spend money to make money. Raising cash is a good sign that production will be ramping up soon.

    Customer pipeline: Growing list of supply and development agreements in place with Sasol, Mansfield Oil, U.S. Air Force, U.S. Army, U.S. Navy, Lanxess, The Coca-Cola Company, Toray, United Airlines and others
    • Deployment status: Commissioned startup of Luverne, Minn. plant and made initial quantities of isobutanol. Currently optimizing technology to ensure isobutanol can be made in consistent and economic volumes
    • Expansion timeline: Second retrofit site identified. Construction set to commence once operational knowledge gained from Luverne is codified into optimal design

  • Time to ramp production and get new contracts. That takes money. I have no problem with the secondary. Great entry level for tomorrow.

  • tomorrow is turnaround friday.

  • no way this stays below a dollar for long! 100 million shares bought yesterday for well over a dollar.Looking for a short cover panic tomorrow.

  • never thought we would fill that gap yesterday. It's done. now lets take it higher where it belongs

GOOG
699.21+7.11(+1.03%)Jul 1 4:00 PMEDT